PL3684370T3 - Kompozycja i leczenie zaniku geograficznego fludrokortyzonem - Google Patents
Kompozycja i leczenie zaniku geograficznego fludrokortyzonemInfo
- Publication number
- PL3684370T3 PL3684370T3 PL19756827.2T PL19756827T PL3684370T3 PL 3684370 T3 PL3684370 T3 PL 3684370T3 PL 19756827 T PL19756827 T PL 19756827T PL 3684370 T3 PL3684370 T3 PL 3684370T3
- Authority
- PL
- Poland
- Prior art keywords
- fludrocortisone
- treatment
- composition
- geographic atrophy
- atrophy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2018900607A AU2018900607A0 (en) | 2018-02-26 | Composition and method of treatment for geographic atrophy or dry amd | |
| PCT/AU2019/000023 WO2019161434A1 (en) | 2018-02-26 | 2019-02-26 | Composition and method of treatment for dry a.m.d. (age related macular degeneration) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3684370T3 true PL3684370T3 (pl) | 2025-07-28 |
Family
ID=67686647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19756827.2T PL3684370T3 (pl) | 2018-02-26 | 2019-02-26 | Kompozycja i leczenie zaniku geograficznego fludrokortyzonem |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210069213A1 (pl) |
| EP (1) | EP3684370B1 (pl) |
| JP (1) | JP7326350B2 (pl) |
| CN (1) | CN111886013A (pl) |
| AU (1) | AU2019225388B2 (pl) |
| ES (1) | ES3035108T3 (pl) |
| PL (1) | PL3684370T3 (pl) |
| WO (1) | WO2019161434A1 (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025507416A (ja) * | 2022-02-15 | 2025-03-18 | アイ コ ピーティーワイ リミテッド | 解剖学的及び機能的な網膜萎縮の治療 |
| CN118490807A (zh) * | 2024-05-09 | 2024-08-16 | 无锡市第二人民医院 | 一种补体C5a在制备治疗眼科疾病药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1755616T1 (sl) * | 2004-04-08 | 2014-04-30 | Eye Co Pty Ltd. | Zdravljenje eksudativne retinopatije z mineralkortikoidi |
| CN106232123A (zh) * | 2013-12-17 | 2016-12-14 | 眼力有限公司 | 玻璃体注射类固醇生物利用度的优化 |
-
2019
- 2019-02-26 WO PCT/AU2019/000023 patent/WO2019161434A1/en not_active Ceased
- 2019-02-26 CN CN201980013523.0A patent/CN111886013A/zh active Pending
- 2019-02-26 PL PL19756827.2T patent/PL3684370T3/pl unknown
- 2019-02-26 AU AU2019225388A patent/AU2019225388B2/en active Active
- 2019-02-26 JP JP2020568005A patent/JP7326350B2/ja active Active
- 2019-02-26 US US16/763,409 patent/US20210069213A1/en active Pending
- 2019-02-26 EP EP19756827.2A patent/EP3684370B1/en active Active
- 2019-02-26 ES ES19756827T patent/ES3035108T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3684370A1 (en) | 2020-07-29 |
| ES3035108T3 (en) | 2025-08-28 |
| CN111886013A (zh) | 2020-11-03 |
| WO2019161434A9 (en) | 2020-05-28 |
| AU2019225388A1 (en) | 2020-04-09 |
| US20210069213A1 (en) | 2021-03-11 |
| EP3684370A4 (en) | 2021-07-07 |
| AU2019225388B2 (en) | 2021-07-08 |
| JP2021515041A (ja) | 2021-06-17 |
| WO2019161434A1 (en) | 2019-08-29 |
| JP7326350B2 (ja) | 2023-08-15 |
| EP3684370C0 (en) | 2025-05-14 |
| EP3684370B1 (en) | 2025-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2582482B (en) | CASZ compositions and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| SG11202004680UA (en) | Cellular compositions and methods of treatment i | |
| IL276135A (en) | Preparations and methods of use | |
| GB202105087D0 (en) | Microbial compositions and methods of use | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| IL275182A (en) | Preparations and methods for the treatment of metabolic conditions | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| EP3606493A4 (en) | DENTAL CEMENT COMPOSITIONS AND METHOD OF USE | |
| GB2568562B (en) | Moldable compositions and methods of using thereof | |
| PL3684370T3 (pl) | Kompozycja i leczenie zaniku geograficznego fludrokortyzonem | |
| IL250852A0 (en) | Periodontal preparation and method of use | |
| GB202115731D0 (en) | Compounds and methods of use | |
| GB201810923D0 (en) | Compositions and method of treatment | |
| ZA202007107B (en) | Compositions comprising pcsk9-binding molecules and methods of use | |
| GB201919385D0 (en) | Compositions and methods of manufacture | |
| GB201919180D0 (en) | New composition of matter | |
| GB201710491D0 (en) | Composition and methods of treatment | |
| HK40065278A (en) | Nanotransposon compositions and methods of use | |
| GB201810925D0 (en) | Compositions and methods of treatment | |
| HK40049684A (en) | Bismuth-thiol compositions and methods of use | |
| ZA202004110B (en) | Compositions and methods for the treatment of metabolic conditions | |
| HK40042765B (en) | Sirt1-sarna compositions and methods of use | |
| HK40042765A (en) | Sirt1-sarna compositions and methods of use |